---
title: "Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients"
id: "circulation-5-laroprovstat-the-first-oral-small-molecule-pcsk9-inhibitor-for-the-treatment-of"
canonical_url: "https://medichelpline.com/clinical-feed/circulation-5-laroprovstat-the-first-oral-small-molecule-pcsk9-inhibitor-for-the-treatment-of"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "Circulation"
source_url: "https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075973?af=R"
published_at: "2026-05-15T09:00:02.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/circulation-5-laroprovstat-the-first-oral-small-molecule-pcsk9-inhibitor-for-the-treatment-of
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** Circulation
- **Source URL:** [Original Journal Publication](https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.075973?af=R)
- **Published At:** 2026-05-15T09:00:02.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Circulation, Volume 153, Issue 25 , Page 1999-2010, June 23, 2026. BACKGROUND:Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective therapy for reducing low-density lipoprotein (LDL) cholesterol (LDL-C) in adults with hyperlipidemia, including heterozygous familial hypercholesterolemia, thereby lowering cardiovascular risk. Current PCSK9 inhibitors are injectable therapies; no oral small-molecule PCSK9 inhibitor has yet been approved.METHODS:Laroprovstat (AZD0780) is a novel small-molecule identified through structure-based design that binds to the PCSK9 C-terminal domain. The effects of laroprovstat on LDL receptor expression and LDL-C levels were assessed in vitro and in mice expressing humanPCSK9. Safety, tolerability, and pharmacokinetic and pharmacodynamic properties of laroprovstat were assessed in healthy participants with LDL-C ≥70 and ≤190 mg/dL after single ascending doses. Laroprovstat was also assessed in participants with LDL-C ≥100 and ≤190 mg/dL at doses of 1 mg or 30 mg versus placebo administered once daily for 28 days after a rosuvastatin 20 mg run-in treatment period.RESULTS:Laroprovstat does not inhibit the PCSK9–LDL receptor interaction but stabilizes the PCSK9 C-terminal domain, preventing lysosomal trafficking and degradation of LDL receptor. Laroprovstat increased LDL receptor expression and reduced LDL-C levels in mice expressing humanPCSK9. Laroprovstat displayed dose-proportional pharmacokinetics and a half-life suitable for once-daily dosing (≈40 hours). There was no clinically meaningful change in exposure when dosed with a high-fat meal compared with the fasted state (area under the plasma concentration-time curveinfand Cmaxgeometric mean reduction of 1.15 [90% CI, 1.11–1.19] and 1.06 [90% CI, 1.00–1.13], respectively). After a rosuvastatin 20 mg 3-week run-in treatment period, laroprovstat 1 and 30 mg reduced LDL-C by 29% (95% CI, 18%–38%) and 51% (95% CI, 44%–58%) compared with baseline. Combined rosuvastatin and laroprovstat treatment resulted in a total approximate reduction in LDL-C of 70% and 80% for laroprovstat 1 and 30 mg, respectively.CONCLUSIONS:Laroprovstat was well tolerated with no safety findings of concern and may be dosed with or without food. In treatment-naïve participants with hypercholesterolemia, combined rosuvastatin 20 mg and laroprovstat 30 mg treatment led to an 80% LDL-C reduction, supporting further development of laroprovstat as the first oral small-molecule PCSK9 inhibitor in patients with hypercholesterolemia.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT05384262.
## Clinical Analysis & Structured Key Points
Circulation, Volume 153, Issue 25 , Page 1999-2010, June 23, 2026. BACKGROUND:Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is an effective therapy for reducing low-density lipoprotein (LDL) cholesterol (LDL-C) in adults with hyperlipidemia, including heterozygous familial hypercholesterolemia, thereby lowering cardiovascular risk. Current PCSK9 inhibitors are injectable therapies; no oral small-molecule PCSK9 inhibitor has yet been approved.METHODS:Laroprovstat (AZD0780) is a novel small-molecule identified through structure-based design that binds to the PCSK9 C-terminal domain. The effects of laroprovstat on LDL receptor expression and LDL-C levels were assessed in vitro and in mice expressing humanPCSK9. Safety, tolerability, and pharmacokinetic and pharmacodynamic properties of laroprovstat were assessed in healthy participants with LDL-C ≥70 and ≤190 mg/dL after single ascending doses. Laroprovstat was also assessed in participants with LDL-C ≥100 and ≤190 mg/dL at doses of 1 mg or 30 mg versus placebo administered once daily for 28 days after a rosuvastatin 20 mg run-in treatment period.RESULTS:Laroprovstat does not inhibit the PCSK9–LDL receptor interaction but stabilizes the PCSK9 C-terminal domain, preventing lysosomal trafficking and degradation of LDL receptor. Laroprovstat increased LDL receptor expression and reduced LDL-C levels in mice expressing humanPCSK9. Laroprovstat displayed dose-proportional pharmacokinetics and a half-life suitable for once-daily dosing (≈40 hours). There was no clinically meaningful change in exposure when dosed with a high-fat meal compared with the fasted state (area under the plasma concentration-time curveinfand Cmaxgeometric mean reduction of 1.15 [90% CI, 1.11–1.19] and 1.06 [90% CI, 1.00–1.13], respectively). After a rosuvastatin 20 mg 3-week run-in treatment period, laroprovstat 1 and 30 mg reduced LDL-C by 29% (95% CI, 18%–38%) and 51% (95% CI, 44%–58%) compared with baseline. Combined rosuvastatin and laroprovstat treatment resulted in a total approximate reduction in LDL-C of 70% and 80% for laroprovstat 1 and 30 mg, respectively.CONCLUSIONS:Laroprovstat was well tolerated with no safety findings of concern and may be dosed with or without food. In treatment-naïve participants with hypercholesterolemia, combined rosuvastatin 20 mg and laroprovstat 30 mg treatment led to an 80% LDL-C reduction, supporting further development of laroprovstat as the first oral small-molecule PCSK9 inhibitor in patients with hypercholesterolemia.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT05384262.
## Related Clinical Research

- [2026 ACC/AHA Dyslipidemia Guideline: Key implications for cholesterol and cardiovascular risk](https://medichelpline.com/clinical-feed/medical-news-today-0-is-your-cholesterol-too-high-per-the-new-acc-aha-guideline-5-things-to-know.md)
- [PBPK-guided Rosuvastatin Dose Adjustments with Ticagrelor by ABCG2 Genotype in Elderly](https://medichelpline.com/clinical-feed/medrxiv-19-pbpk-model-based-prediction-of-optimal-rosuvastatin-dosing-with-concomitant.md)
- [Clinicians’ Views on “Fighting the Ventilator”: Survey of ICU Practice and Gaps](https://medichelpline.com/clinical-feed/medrxiv-23-clinicians-perspectives-on-fighting-the-ventilator.md)
- [Metabolic and Safety Outcomes of Statin–Ezetimibe Versus High‐Intensity Statin in Older Patients](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-56-metabolic-and-safety-outcomes-of-statin-ezetimibe-versus-high-intensity-statin.md)
- [Atorvastatin-loaded frankincense SNEDDS thermoresponsive hydrogel improves wound healing in a rat](https://medichelpline.com/clinical-feed/pubmed-42542257.md) (DOI: 10.1016/j.ijpharm.2026.127264)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.